Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma

Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E.

LUNG CANCER, cilt.57, sa.1, ss.79-83, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 1
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.lungcan.2007.02.009
  • Dergi Adı: LUNG CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.79-83
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Topotecan is an active agent for the management of untreated and recurrent extensive-disease small cell tung cancer, (ED-SCLC). This study was designed to evaluate the efficacy and safety of a triplet combination with topotecan added to the standard PE regimen in previously untreated patients with ED-SCLC.